First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties
The Journal of Pharmacology and Experimental Therapeutics · 2025-03 · 392 (3) · 100031
DOI: 10.1124/jpet.124.002281 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025-03. Verfasst von Mohan E Tulapurkar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: mtulapurkar@som.umaryland.edu. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GEn1E Lifesciences, National Institutes of Health, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
We previously identified a small molecule, UM101, predicted to bind to the substrate-binding groove of p38α mitogen-activated protein kinase (MAPK) near the binding site of its proinflammatory substrate, mitogen-activated protein kinase-activated protein kinase (MK)2. UM101 exhibited anti-inflammatory, endothelial-stabilizing, and lung-protective effects. To overcome its limited aqueous solubility and p38α binding affinity, we designed an analog of UM101, GEn-1124, with improved aqueous solubility, stability, and p38α-binding affinity. Compared with UM101, GEn-1124 has 18-fold greater p38α-binding affinity as measured by surface plasmon resonance, 11-fold greater aqueous solubility, enhanced barrier-stabilizing activity in thrombin-stimulated human pulmonary artery endothelial cells in vitro, and greater lung protection in vivo. GEn-1124 improved survival from 10%-40% in murine acute lung injury induced by combined exposure to intratracheal bacterial endotoxin lipopolysaccharide instillation and febrile-range hyperthermia and from 0% to 50% in a mouse influenza pneumonia model. Gene expression analysis by RNASeq in tumor necrosis factor α-treated human pulmonary artery endothelial cells showed that the gene-modifying effects of GEn-1124 were much more restricted to tumor necrosis factor α-inducible genes than those of the catalytic site p38 inhibitor, SB203580. Gene expression pathway analysis, confocal immunofluorescence analysis of p38α and MK2 subcellular trafficking, and surface plasmon resonance analysis of phosphorylated p38α:MK2 binding affinity supports a novel mechanism of action. GEn-1124 destabilizes the activated p38α:MK2 complex and dissociates nuclear export of MK2 and p38α, thereby promoting intranuclear retention and enhanced intranuclear signaling by phosphorylated p38α and accelerated inactivation of p38-free cytosolic MK2 by unopposed phosphatases. SIGNIFICANCE STATEMENT: We describe a novel analog of our first-in-class small molecule modulator of p38α/MK2 signaling targeted to a pocket near the glutamate-aspartate-containing substrate binding domain of p38α, which destabilizes the p38α:MK2 complex without blocking p38 catalytic activity or ablating downstream signaling. The result is a rebalancing of downstream proinflammatory and anti-inflammatory signaling, yielding anti-inflammatory, endothelial-stabilizing, and lung-protective effects with therapeutic potential in acute respiratory distress syndrome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: mtulapurkar@som.umaryland.edu.
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland.
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Medicine and Research Services of the Baltimore VA Medical Center, Baltimore, Maryland.
- GEn1E Lifesciences, Palo Alto, California.
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland.
Förderung
- GEn1E Lifesciences
- National Institutes of Health
- U.S. Department of Veterans Affairs
- Institute for Clinical and Translational Research, University of Wisconsin, Madison
- Veterans Health Administration Biomedical Laboratory Research and Development
Zitieren
APA
Tulapurkar, M. E., Shirey, K. A., Lugkey, K., Luo, W., Lal, R., Galan, A., Mahmoud, O., McClean, N., Thangaraju, K., Cericola, D., Lewis, D., Murphy, W. A., Fletcher, S., MacKerell, A. D., Vogel, S. N., Shapiro, P., & Hasday, J. D. (2025). First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties. The Journal of Pharmacology and Experimental Therapeutics, 392(3), 100031. https://doi.org/10.1124/jpet.124.002281
Vancouver
Tulapurkar ME, Shirey KA, Lugkey K, Luo W, Lal R, Galan A, et al. First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties. The Journal of Pharmacology and Experimental Therapeutics. 2025;392(3):100031. doi:10.1124/jpet.124.002281
BibTeX
@article{Tulapurkar2025,
author = {Tulapurkar, Mohan E and Shirey, Kari Ann and Lugkey, Katerina and Luo, Wendy and Lal, Ritu and Galan, Adam and Mahmoud, Omar and McClean, Nathaniel and Thangaraju, Kiruphagaran and Cericola, Daniel and Lewis, Daniel and Murphy, William A and Fletcher, Steven and MacKerell, Alexander D and Vogel, Stefanie N and Shapiro, Paul and Hasday, Jeffrey D},
title = {First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2025},
volume = {392},
number = {3},
pages = {100031},
doi = {10.1124/jpet.124.002281}
}
EUVIMED